Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (Diluted Average) (2020 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Shares Outstanding (Diluted Average) for 8 consecutive years, with $28.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 35.36% year-over-year to $28.7 million, compared with a TTM value of $28.7 million through Dec 2025, up 35.36%, and an annual FY2025 reading of $21336.0, up 0.85% over the prior year.
  • Shares Outstanding (Diluted Average) was $28.7 million for Q4 2025 at Enanta Pharmaceuticals, up from $21336.0 in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $28.7 million in Q4 2025 and bottomed at $20171.0 in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $15.6 million, with a median of $20.8 million recorded in 2022.
  • Peak annual rise in Shares Outstanding (Diluted Average) hit 35.36% in 2025, while the deepest fall reached 0.6% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $20.4 million in 2021, then rose by 2.1% to $20.8 million in 2022, then increased by 1.31% to $21.1 million in 2023, then grew by 0.71% to $21.2 million in 2024, then skyrocketed by 35.36% to $28.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for ENTA at $28.7 million in Q4 2025, $21336.0 in Q3 2025, and $21.4 million in Q2 2025.